伊布替尼联合CD19嵌合抗原受体T细胞治疗慢性淋巴细胞白血病的研究进展  

Progress of ibrutinib combined with CD19 chimeric antigen receptor T-cell in treatment of chronic lymphocytic leukemia

作　　者：焦俊 刘芹芹[1] 滕清良[1] 王玲[1] Jiao Jun;Liu Qinqin;Teng Qingliang;Wang Ling(Department of Hematology,Taian City Central Hospital of Shandong Province,Taian 271000,China)

机构地区：[1]山东省泰安市中心医院血液科,泰安271000

出　　处：《白血病．淋巴瘤》2023年第7期445-448,共4页Journal of Leukemia & Lymphoma

基　　金：山东省医药卫生科技发展计划面上项目(2019WS212、202003040818)。

摘　　要：慢性淋巴细胞白血病(CLL)是一种B淋巴细胞的克隆性恶性疾病(T淋巴细胞少见),好发于老年人,且有高度可变的临床过程,中位生存期一般为35~63个月。在免疫化疗时代,CLL患者的生存得到明显改善,但仍有大部分患者存在原发耐药及治疗后复发。布鲁顿酪氨酸激酶抑制剂的出现彻底改变了CLL的治疗模式,使CLL的治疗进入靶向时代,伊布替尼联合CD19嵌合抗原受体T细胞治疗具有较好的效果,可改善患者预后。Chronic lymphocytic leukemia(CLL)is a clonal malignant disease of B lymphocytes(T lymphocytes are rare)and usually occurs in elderly people.CLL has a highly variable clinical course,with a median survival of 35 to 63 months.In the era of immunochemotherapy,the survival of CLL patients has improved significantly,but most patients still have primary drug resistance and relapse after the treatment.The emergence of Bruton tyrosine kinase inhibitor has completely changed the treatment mode of CLL,making the treatment of CLL into the era of targeted therapy.Ibrutinib combined with CD19 chimeric antigen receptor T-cell has good efficacy and can improve the prognosis of patients.

关 键 词：白血病 淋巴细胞 慢性 伊布替尼 CD19 嵌合抗原受体T细胞 

分 类 号：R733.72[医药卫生—肿瘤]